PetMed Express faces a critical inflection point as its legacy transactional model struggles to compete against integrated e-commerce platforms, resulting in a 21.13% year-over-year revenue decline. The company's inability to scale fixed costs has pushed opera...
Price trend, volume and key moving averages
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 13, 2026 | -$0.28-333.3% vs $0.12 | $41M-42.2% vs $71M |
Q3 2026 Jun 2, 2026 | -$0.19-5.6% vs -$0.18 | $43M-17.7% vs $52M |
Q1 2026 Feb 5, 2026 | -$0.50-733.3% vs -$0.06 | $41M-24.8% vs $54M |
Q4 2025 Dec 19, 2025 | -$0.34-1600.0% vs -$0.02 | $44M-36.0% vs $69M |
DELRAY BEACH, Fla., Sept. 14, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx (Nasdaq: PETS), today announced the appointment of Andrew Parry as Chief Technology Officer, effective immediately. Parry will lead the Company's technology strategy, platform architecture and engineering execution across its e-commerce, pharmacy and enterprise systems.
Carvana (NYSE: CVNA - Get Free Report) and PetMed Express (NASDAQ: PETS - Get Free Report) are both consumer discretionary companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings. Risk and Volatility Carvana has a beta of
PETS' fiscal first-quarter 2027 sales decline year over year, but lower costs, stronger recurring sales and new partnerships offer signs of progress.
PetMed (PETS) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of $0.12. This compares to a loss of $0.34 per share a year ago.
Benchmark PETS against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for PetMed Express, Inc. (PETS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.57 | $33.55M | -0.57 | -21.13% | -32% | -100.44% | 0.06% | |
| $19.66 | $8.14B | 37.81 | 6.24% | 1.68% | 49.51% | — | |
| $2.39 | $682.5M | 75.39 | -2.53% | 0.1% | 0.49% | — | |
| $60.13 | $2.95B | 22.78 | 13.01% | 17.28% | 16.65% | — | |
| $30.43 | $6.79B | 59.67 | 59% | -5.51% | -30.03% | — | |
| $6.35 | $1.15B | -5.57 | -1.54% | -7.13% | -13.08% | — |
PetMed Express, Inc. (PETS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
PetMed Express, Inc. (PETS) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 13, 2026·SEC
Aug 12, 2026·SEC
Jul 23, 2026·SEC
Get notified when PETS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PetMed Express, Inc. (PETS) stock FAQ — growth, dividends, profitability & financials explained
PetMed Express, Inc. (PETS) reported $168.9M in revenue for fiscal year 2026. This represents a 1050% increase from $14.7M in 2000.
PetMed Express, Inc. (PETS) saw revenue decline by 21.1% over the past year.
PetMed Express, Inc. (PETS) reported a net loss of $29.3M for fiscal year 2026.
PetMed Express, Inc. (PETS) does not currently pay a meaningful dividend. The company may be reinvesting profits for growth.
PetMed Express, Inc. (PETS) has a return on equity (ROE) of -100.4%. Negative ROE indicates the company is unprofitable.
PetMed Express, Inc. (PETS) had negative free cash flow of $27.8M in fiscal year 2026, likely due to heavy capital investments.
